CSIMarket
 
Abbvie inc   (ABBV)
Other Ticker:  
 
 
Price: $178.4900 $0.61 0.343%
Day's High: $179.88 Week Perf: -1.34 %
Day's Low: $ 177.57 30 Day Perf: 1.08 %
Volume (M): 8,569 52 Wk High: $ 182.89
Volume (M$): $ 1,529,517 52 Wk Avg: $152.09
Open: $179.01 52 Wk Low: $130.96



 Market Capitalization (Millions $) 319,117
 Shares Outstanding (Millions) 1,788
 Employees 50,000
 Revenues (TTM) (Millions $) 54,318
 Net Income (TTM) (Millions $) 4,873
 Cash Flow (TTM) (Millions $) 3,613
 Capital Exp. (TTM) (Millions $) 777

Abbvie Inc

AbbVie is a global, research-based biopharmaceutical company formed in 2013 following separation from Abbott. The company’s mission is to use its expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world’s most complex and serious diseases.

Distribution       

The Pharmaceutical Products segment markets its products in the United States and generally sells its products directly to wholesalers, government agencies, health care facilities and independent retailers from Abbott-owned distribution centers and public warehouses. This segment directs its primary marketing efforts toward securing the prescription of Abbotts brand of products by physicians. Managed care purchasers (for example, health maintenance organizations and pharmacy benefit managers) and state and federal governments and agencies (for example, the Department of Veterans Affairs and the Department of Defense) are also important customers.    

In addition, under its strategic alliance with Celera Diagnostics, a joint venture between the Applied Biosystems Group and the Celera Genomics Group of Applera Corporation, the Diagnostic Products segment develops, manufactures and markets a broad range of in vitro molecular diagnostic products for disease detection, disease progression monitoring and therapy selection. Through a sales and marketing agreement with Enfer Scientific Ltd., the Diagnostic Products segment also distributes diagnostic tests in Europe and Japan that are used to detect bovine spongiform encephalopathy (BSE) in cattle.

        The Diagnostic Products segment markets its products worldwide. These products are generally marketed and sold directly to hospitals, laboratories, clinics, and physicians offices from Abbott-owned distribution centers and public warehouses. Outside the United States, sales are made either directly to customers or through distributors, depending on the market served. Blood glucose monitoring meters and test strips for people with diabetes are also sold over the counter to consumers.

     The Hospital Products segments principal products also include venipuncture products and Faultless' rubber sundry products.

        The Hospital Products segment markets its products primarily in the United States. This segments products are generally distributed from Abbott-owned distribution centers and public warehouses to wholesalers and directly to hospitals, integrated delivery networks, and other alternate site locations where patient care is delivered. The Hospital Products segment also develops and manufactures injectable pharmaceuticals for other companies.  

Competition in the Pharmaceutical Products segment is generally from other health care and pharmaceutical companies. The search for technological innovations in pharmaceutical products is a significant aspect of competition in this segment. The introduction of new products by competitors and changes in medical practices and procedures can result in product obsolescence in the Pharmaceutical Products segment, and price can also be a factor. In addition, the substitution of generic drugs for the brand prescribed has increased competitive pressures on pharmaceutical products which are off-patent.

      Competition for the International segments pharmaceutical products is generally from other health care and pharmaceutical companies. A significant aspect of competition is the search for technological innovations. The introduction of new products by competitors and changes in medical practices and procedures can result in product obsolescence. Price can also be a factor. In addition, the substitution of generic drugs for the brand prescribed has increased competitive pressures on pharmaceutical products. Competition for the segments nutritional products is generally from other health care manufacturers and food companies. Nutritional products are subject to competition in price, scientific innovation, formulation, and promotional initiatives. The International segments hospital products are subject to competition in technological innovation, price, convenience of use, product warranty provisions, service, product performance, long-term supply contracts, and product potential for overall cost effectiveness and productivity gains. Products in this segment can be subject to rapid product obsolescence. Although Abbott has benefitted from technological advantages of certain of its current products, these advantages may be reduced or eliminated as competitors introduce new products.



   Company Address: 1 North Waukegan Road North Chicago 60064 IL
   Company Phone Number: 932-7900   Stock Exchange / Ticker: NYSE ABBV
   


Customers Net Income fell by ABBV's Customers Net Profit Margin fell to

-11.5 %

2.66 %

• Customers Performance • Customers Expend. • Customers Efficiency • List of Customers


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ABT   -6.89%    
BMY   -5.17%    
JNJ   -3.67%    
LLY        1.02% 
MRK   -0.99%    
PFE   -1.04%    
• View Complete Report
   



Abbvie Inc

AbbVie Inc. Faces Revenue Decline in Q4 2023 Amidst Healthcare Breakthroughs2.

Amidst the backdrop of a turbulent financial quarter for AbbVie Inc., recent developments in the healthcare sector have emerged as a beacon of hope for patients dealing with hard-to-treat follicular lymphoma. Genmab A/S and AbbVie's innovative bispecific antibody epcoritamab has shown promising results in their ongoing clinical trial, with an overall response rate of 82 percent and a complete response rate of 63 percent. This breakthrough in treatment options is certainly a positive development in the healthcare industry.
However, despite these positive advancements in the healthcare sector, AbbVie Inc. has been facing operational challenges, as evidenced by their recent financial figures. The company reported a decrease in revenue by -5.423% to $14.30 billion for the fourth quarter of 2023, leading to a significant drop in profitability by -66.54%. Earnings per share also took a hit, declining by -53.53% from the prior quarter.

Product Service News

Epcoritamab Shows Potential in Treating Refractory Follicular Lymphoma, as AbbVie Grapples with Rising Operational Costs Amid Slowing Revenues

Published Sat, Dec 9 2023 5:00 PM UTC


COPENHAGEN, Denmark - New pivotal data introduced an innovative beacon of hope for patients dealing with hard-to-treat follicular lymphoma (FL). Genmab A/S (Nasdaq: GMAB) and AbbVie (NYSE: ABBV) announced promising results from their ongoing phase 1/2 EPCORE NHL-1 clinical trial investigation, focusing on the bispecific antibody epcoritamab (DuoBody CD3xCD20). Administe...

Abbvie Inc

Abbvie Inc. Navigates Economic Hurdles as Revenue Dips by a Marginal Rate in the Financial Span Ending Sep 30, 2023



Abbvie Inc, a major player in the Pharmaceutical Preparations sector, recently reported its financial results for the time-frame ending September 30, 2023. The company experienced significant setbacks in key financial performance indicators, including income per share, profits, and revenue. This article aims to interpret these results and discuss the potential implications for AbbVie Inc going forward.
Income Per Share and Profit Declines:
Abbvie Inc encountered a sharp decline in income per share, recording a staggering -54.75% decrease to $1.00 per share compared to $2.21 per share the previous year. Furthermore, profits fell by -12.28% in the preceding quarter, resulting in a decrease from $1.14 per share to an alarming level. These figures indicate a challenging financial period for AbbVie Inc, raising concerns about the company's profitability and future growth prospects.

Abbvie Inc

Abbvie Inc's Q2 2023 Results: Surprising Growth in EPS, but Troubling -4.924% Drop in Revenue Raises Concerns for Future Growth



Abbvie Inc, a leading pharmaceutical company, recently released its financial results for the second quarter of 2023. While the company managed to improve its earnings per share (EPS) and income per share, it faced challenges in terms of decreasing revenue and increasing inventories. These results provide interesting insights into the company's current financial standing and leave us wondering about its implications for future growth.
EPS and Income Per Share Improvement:
Despite soft orders in the second quarter, Abbvie Inc saw a substantial increase in EPS, with income per share advancing by an impressive 123.53% to $1.14 per share. This indicates the company's ability to efficiently manage its resources and generate higher profits per share. However, it is worth questioning whether this growth can be sustained in the long term.

Abbvie Inc

Abbvie Inc's Income Plunges by 94.82%: What's Next for the Biopharmaceutical Giant?

Abbvie Inc is a biopharmaceutical company that specializes in the discovery, development, and commercialization of advanced therapies for the treatment of a range of health conditions. The company was established in 2013 as a spin-off from Abbott Laboratories, and since then, it has grown into a leading player in the pharmaceutical industry.
However, Abbvie Inc has recently reported a significant drop in revenues and income, causing concern among investors and industry analysts. In the financial span ending March 31, 2023, the company's income plummeted by -94.82% to $0.13 per share, compared to $2.51 per share in the same period the previous year.






 

Abbvie Inc's Segments
 
HUMIRA
 Segment     of total Revenue
Kaletra
 Segment     of total Revenue
AndroGel
 Segment     of total Revenue
Lupron
 Segment     of total Revenue
Synthroid
 Segment     of total Revenue
Other
 Segment     of total Revenue
Synagis
 Segment     of total Revenue
Sevoflurane
 Segment     of total Revenue
Creon
 Segment     of total Revenue
VIEKIRA
 Segment     of total Revenue
Dyslipidemia products
 Segment     of total Revenue
 
• View Complete Report
  Company Estimates  
  Revenue Outlook
Abbvie Inc does not provide revenue guidance.

Earnings Outlook
Abbvie inc issued annual earnings guidance on

 
Geographic Revenue Dispersion
United States
Japan
Germany
Canada
The Netherlands
Italy
All Other Countries
Brazil
Spain
France




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com